J.P. Morgan 38th Annual Healthcare Conference (JPM 2020)
60 days until the J.P. Morgan 38th annual Healthcare Conference (#JPM2020). Removing the upcoming holidays and weekends, we’re talking 36 [...]
EASD 2019: Vault Bioventures’ Observations
Slowly, but ever so surely, the diabetes treatment landscape is evolving along two continuums. The first is the world of [...]
79th American Diabetes Association
Diabetes, once considered a disease of the pancreas, is now understood to be a complex, multi-hormonal disease leading to devastating [...]
Pharma Industry News Weekly Recap: November 1, 2018
Pharma’s ‘Come-to-Jesus Moment’: The Industry Braces for a Pelosi Speakership & Democrats’ Drug Pricing Agenda October 30, 2018 PharmaNancy [...]
Jardiance Asks: Consumer Campaign
Boehringer Ingelheim & Eli Lilly and Evoke Health for Jardiance Jardiance Asks: Consumer Campaign An authentic approach successfully [...]
CHMP Issues Positive Opinion To Expand Jardiance®, Synjardy® And Glyxambi® Labels To Include Positive Effects On Cardiovascular And Renal Outcomes
INGELHEIM, Germany & INDIANAPOLIS–(BUSINESS WIRE)–Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency (EMA) [...]
Novo’s oral semaglutide bests Lilly and Boehringer Ingelheim’s Jardiance in phase 3, but questions remain
Even as Novo Nordisk works to steal diabetes market share with its new GLP-1 drug Ozempic, it’s advancing an oral [...]
FDA Approves Aimovig for Migraine Prevention
The U.S. Food and Drug Administration has approved erenumab (Aimovig™, Amgen and Novartis), a first-in-class calcitonin gene-related peptide (CGRP) antagonist, [...]